Uniqure Nv Stock Performance
| QURE Stock | USD 11.67 0.68 6.19% |
Uniqure NV holds a performance score of 9 on a scale of zero to a hundred. The entity has a beta of 0.24, which indicates not very significant fluctuations relative to the market. As returns on the market increase, Uniqure NV's returns are expected to increase less than the market. However, during the bear market, the loss of holding Uniqure NV is expected to be smaller as well. Use Uniqure NV semi variance, and the relationship between the treynor ratio and daily balance of power , to analyze future returns on Uniqure NV.
Risk-Adjusted Performance
OK
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Uniqure NV are ranked lower than 9 (%) of all global equities and portfolios over the last 90 days. In spite of rather uncertain basic indicators, Uniqure NV exhibited solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 6.19 | Five Day Return (10.09) | Year To Date Return (35.35) | Ten Year Return (49.78) | All Time Return (20.12) |
Last Split Factor 1:5 | Last Split Date 2014-01-31 |
1 | Acquisition by Christian Klemt of 3672 shares of Uniqure NV subject to Rule 16b-3 | 12/06/2024 |
2 | 11,699 Shares in uniQure Bought by Quarry LP | 12/10/2024 |
3 | Acquisition by Springhorn Jeremy P. of 17060 shares of Uniqure NV at 20.18 subject to Rule 16b-3 | 01/08/2025 |
4 | Analyzing Wright Medical Group and uniQure | 01/13/2025 |
5 | Clear Harbor Asset Management LLC Sells 2,500 Shares of uniQure | 01/23/2025 |
6 | HC Wainwright Forecasts uniQure FY2029 Earnings - MarketBeat | 01/28/2025 |
7 | uniQure Announces Favorable Recommendation from Independent Data Monitoring Committee for its Phase III EPISOD1 Clinical Trial of AMT-162 for the Treatment of S... | 01/30/2025 |
8 | uniQure Announces Completion of Enrollment in the First Cohort and Favorable Recommendation from the Independent Data Monitoring Committee for its Phase IIIa Cl... | 02/03/2025 |
9 | uniQure CSL Behrings Hemophilia Gene Therapy Shows Sustained Efficacy and Safety At Four Years | 02/07/2025 |
10 | uniQure Trading Down 9.5 percent Whats Next | 02/24/2025 |
| Begin Period Cash Flow | 231.2 M |
Uniqure |
Uniqure NV Relative Risk vs. Return Landscape
If you would invest 597.00 in Uniqure NV on November 29, 2024 and sell it today you would earn a total of 570.00 from holding Uniqure NV or generate 95.48% return on investment over 90 days. Uniqure NV is currently generating 1.8965% in daily expected returns and assumes 15.3589% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Uniqure, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Uniqure NV Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Uniqure NV's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Uniqure NV, and traders can use it to determine the average amount a Uniqure NV's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1235
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | QURE | |||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 15.36 actual daily | 96 96% of assets are less volatile |
Expected Return
| 1.9 actual daily | 37 63% of assets have higher returns |
Risk-Adjusted Return
| 0.12 actual daily | 9 91% of assets perform better |
Based on monthly moving average Uniqure NV is performing at about 9% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Uniqure NV by adding it to a well-diversified portfolio.
Uniqure NV Fundamentals Growth
Uniqure Stock prices reflect investors' perceptions of the future prospects and financial health of Uniqure NV, and Uniqure NV fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Uniqure Stock performance.
| Return On Equity | -1.48 | ||||
| Return On Asset | -0.17 | ||||
| Operating Margin | (17.77) % | ||||
| Current Valuation | 255.97 M | ||||
| Shares Outstanding | 53.44 M | ||||
| Price To Earning | 2.51 X | ||||
| Price To Book | 11.17 X | ||||
| Price To Sales | 21.81 X | ||||
| Revenue | 15.84 M | ||||
| Gross Profit | (154.08 M) | ||||
| EBITDA | (253.1 M) | ||||
| Net Income | (308.48 M) | ||||
| Cash And Equivalents | 500.52 M | ||||
| Cash Per Share | 10.71 X | ||||
| Total Debt | 138.41 M | ||||
| Debt To Equity | 0.29 % | ||||
| Current Ratio | 10.84 X | ||||
| Book Value Per Share | 1.15 X | ||||
| Cash Flow From Operations | (145.93 M) | ||||
| Earnings Per Share | (5.26) X | ||||
| Market Capitalization | 623.61 M | ||||
| Total Asset | 831.69 M | ||||
| Retained Earnings | (890.41 M) | ||||
| Working Capital | 578.18 M | ||||
| Current Asset | 209.49 M | ||||
| Current Liabilities | 24.38 M | ||||
About Uniqure NV Performance
By analyzing Uniqure NV's fundamental ratios, stakeholders can gain valuable insights into Uniqure NV's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Uniqure NV has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Uniqure NV has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 289.84 | 304.33 | |
| Return On Tangible Assets | (0.37) | (0.39) | |
| Return On Capital Employed | (0.34) | (0.35) | |
| Return On Assets | (0.33) | (0.35) | |
| Return On Equity | (1.71) | (1.62) |
Things to note about Uniqure NV performance evaluation
Checking the ongoing alerts about Uniqure NV for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Uniqure NV help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Uniqure NV is way too risky over 90 days horizon | |
| Uniqure NV appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 15.84 M. Net Loss for the year was (308.48 M) with loss before overhead, payroll, taxes, and interest of (154.08 M). | |
| Uniqure NV currently holds about 500.52 M in cash with (145.93 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 10.71. | |
| Uniqure NV has a frail financial position based on the latest SEC disclosures | |
| Over 79.0% of the company shares are owned by institutional investors | |
| Latest headline from thelincolnianonline.com: uniQure Trading Down 9.5 percent Whats Next |
- Analyzing Uniqure NV's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Uniqure NV's stock is overvalued or undervalued compared to its peers.
- Examining Uniqure NV's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Uniqure NV's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Uniqure NV's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Uniqure NV's stock. These opinions can provide insight into Uniqure NV's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Uniqure Stock analysis
When running Uniqure NV's price analysis, check to measure Uniqure NV's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Uniqure NV is operating at the current time. Most of Uniqure NV's value examination focuses on studying past and present price action to predict the probability of Uniqure NV's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Uniqure NV's price. Additionally, you may evaluate how the addition of Uniqure NV to your portfolios can decrease your overall portfolio volatility.
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes |